53
Participants
Start Date
March 17, 2021
Primary Completion Date
June 19, 2024
Study Completion Date
June 19, 2024
PF-07284892
PF-07284892
lorlatinib
lorlatinib
binimetinib
binimetinib
cetuximab
cetuximab
encorafenib
encorafenib
Memorial Sloan Kettering Cancer Center David H Koch Center for Cancer Care, New York
Memorial Sloan Kettering Cancer Center Rockefeller Outpatient Pavilion, New York
Tennessee Oncology PLLC, Franklin
Tennessee Oncology, PLLC, Franklin
Sarah Cannon Research Institute- Pharmacy, Nashville
SCRI Oncology Partners, Nashville
Tennessee Oncology PLLC, Nashville
Tennessee Oncology, PLLC, Nashville
Brigitte Harris Cancer Pavilion, Detroit
Henry Ford Hospital, Detroit
Henry Ford Medical Center - Columbus, Novi
START Midwest, Grand Rapids
University of Iowa, Iowa City
Mayo Clinic in Rochester, Minnesota, Rochester
The University of Texas MD Anderson Cancer Center, Houston
Mayo Clinic in Arizona - Phoenix, Phoenix
Mayo Clinic, Scottsdale
California Cancer Associates for Research and Excellence, Encinitas
California Cancer Associates for Research and Excellence, San Marcos
Lead Sponsor
Pfizer
INDUSTRY